Clinical trials: CYP2C19 Polymorphism
Healthy
Study the Effects of CYP2C Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide
The aims of this study were to investigate the effects of CYP2C9 and CYP2C19 polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in healthy Chinese subjects.
- Trial name
- NCT00806013
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Sciences
Genotype, Pharmacokinetic
Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects
Diabetes mellitus is a growing global disease now and future, and in China, 1.2 million peoples per year have been diagnosed as diabetes mellitus. 90% diabetes mellitus patient is Type 2 diabetes mellitus.
- Trial name
- NCT01082796
- Testing
- Glipizide
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Sciences
Healthy
Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism
To study the impact of CYP2C19 polymorphism on escitalopram pharmacokinetics and pharmacodynamics measured as changes in pupil diameter
- Trial name
- NCT00397059
- Testing
- Escitalopram
- Where
- Denmark
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Southern Denmark
Stomach Ulcer
Influence of CYP2C19 Polymorphism on PK/PD of Omeprazole
A clinical trial to investigate the influence of CYP2C19 polymorphism on pharmacokinetic/pharmacodynamic characteristics of omeprazole in healthy Korean volunteers
- Trial name
- NCT02299687
- Testing
- Omeprazole
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Healthy
Bioavailability and Metabolism of Voriconazole in Relation to Its Modulation by the CYP2C19 Genetic Polymorphism
The purposes of this study are: To determine the absolute bioavailability of voriconazole after a single oral dose (400 mg voriconazole [VFEND brand]) in comparison to intravenous (i.v.) administration (400 mg VFEND, equivalent…
- Trial name
- NCT00175994
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Heidelberg University
Healthy
Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects
To test pharmacodynamic response to clopidogrel 150mg once daily during 7 days in healthy subjects carriers of a mutated allele (*2) associated with CYP2C19 deficiency and non responders to the usual regimen of 75 mg once daily
- Trial name
- NCT00413608
- Testing
- Clopidogrel
- Where
- France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
CYP2C19 Polymorphism, H.Pylori Infection
Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication
Background: Triple therapy efficacy against Helicobacter pylori is low worldwide, thus alternatives must be sought to improve eradication. Aim: To determine CYP2C19 genetic polymorphism effect on H. pylori eradication.
- Conditions
- CYP2C19 Polymorphism, H.Pylori Infection, Therapy
- Trial name
- NCT03650543
- Testing
- amoxicillin clarithromycin omeprazole 1, amoxicillin clarithromycin omeprazole 2
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Javeriana University
Interaction
The Effect of Genetic Polymorphism on Interactions of Clopidogrel and Cilostazol in Healthy Volunteers
The aim of this study is to investigate the effects of genetic polymorphisms on pharmacokinetic and pharmacodynamic interactions of clopidogrel and cilostazol in Korean healthy adult volunteers.
- Trial name
- NCT01482117
- Testing
- Clopidogrel, Cilostazol, Clopidogrel/Cilostazol
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Inje University
Coronary Artery Disease
Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole
Clopidogrel, an inhibitor of ADP induced platelet aggregation and activation, is one of the most commonly used drugs in patients with cardiovascular disease.
- Trial name
- NCT01094275
- Testing
- Clopidogrel 75mg, Omeprazole 20mg
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Neil Kleiman, MD
Acute Coronary Syndrome, CYP2C19 Polymorphism
POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy
The goal of this pilot clinical trial is to test the safety and effectiveness of genotype-guided clopidogrel monotherapy in patients presenting with Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) who have undergone…
- Trial name
- POPular GUILTY (NCT05926271)
- Testing
- Clopidogrel
- Where
- Netherlands
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- St. Antonius Hospital
Depression
A Genotype Stratification Study for Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Male Subjects
A total of 24 healthy Korean male subjects will receive a single oral dose of amitriptyline, 25 mg. Subjects will be enrolled in this study based on their cytochrome P450 2D6 and cytochrome P450 2C19 genotypes, and serial blood…
- Trial name
- NCT02519400
- Testing
- Amitriptyline
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
Kidney Diseases
Chinese Herb Nephropathy Epidemiology and Association With CYP2D6, CYP2C19, PXR, or MDR1 Polymorphism
1. Chinese herb nephropathy (CHN), a kind of kidney failure caused by Chinese herbs, may be related to the a component called aristolochic acid (AA). 2.
- Trial name
- NCT01503645
- Where
- 2 sites in Taiwan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Healthy Volunteers
Influence of SLCO2B1 Polymorphism on the PK of Voriconazole in CYP2C19 PM
A clinical trail to investigate the influence of SLCO2B1 polymorphism on the pharmacokinetic characteristics of voriconazole in CYP2C19 poor metabolizers
- Trial name
- NCT02906176
- Testing
- Vfend (voriconazole) intravenous infusion, Vfend (voriconazole) tablet
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Healthy
Risk of CYP2C19 Phenoconversion in Healthy Volunteers With Rapid, Normal, and Intermediate Predicted Metabolizers' Status
CYP2C19 is responsible for the metabolism of approximately 10% of drugs currently on the market, including several proton pump inhibitors, clopidogrel, benzodiazepines and some tricyclic antidepressants, including amitriptyline.
- Trial name
- Switch19 (NCT05264142)
- Testing
- Voriconazole 200mg, FluvoxaMINE 50 Mg Oral Tablet, Omeprazole 10 MG Oral Tablet
- Where
- Switzerland
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva